This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Halvorsen, O. J. Articles by Akslen, L. A. Search for Related Content PubMed PubMed Citation Articles by Halvorsen, O. J. Articles by Akslen, L. A.

Combined Loss of PTEN and p27 Expression Is Associated with Tumor Cell Proliferation by Ki-67 and Increased Risk of Recurrent Disease in Localized Prostate Cancer¹

Department of Pathology, The Gade Institute [O. J. H., L. A. A.] and Section of Urology, Department of General Surgery [S. A. H.], Haukeland University Hospital, N-5021 Bergen, Norway

Purpose: Recent experimental work indicates a major role for PTEN and p27 in prostate cancer. The combined loss of PTEN and p27 was found to strongly increase the development of prostatic carcinomas in an animal model, and a prognostic value in human tumors was postulated. The purpose of our study was to examine the impact of PTEN and p27 on prognosis in a series of prostate cancer patients, using high-density tissue microarray technology for expression profile analysis of PTEN, p27, and tumor cell proliferation.

Experimental Design: The expression of PTEN and p27 was examined in primary prostatic carcinomas from 104 patients treated with radical prostatectomy and with complete follow-up available. Using high-throughput tissue microarrays, the expression of PTEN and p27 was examined by immunohistochemistry, and the results were related to clinicopathological variables, tumor cell proliferation (Ki-67), and time to disease progression.

Results: PTEN was negative in 28 of 103 tumors (27.2%), and median p27 expression was 64%. Combined loss of PTEN and p27 expression defined a group of 18 tumors (17.5%) associated with increased tumor diameter, seminal vesicle invasion, increased pathological stage, and elevated tumor cell proliferation by Ki-67. Cox regression analysis revealed that loss of PTEN/p27 expression and histological grade were both independent predictors of time to biochemical failure and clinical recurrence.

Conclusions: Our findings strongly support the importance of PTEN and p27 for the progression of human prostate cancer because loss of PTEN/p27 expression was associated with adverse pathological parameters, tumor cell proliferation, and increased risk of recurrence.

This article has been cited by other articles:

				K. Gravdal, O. J. Halvorsen, S. A. Haukaas, and L. A. Akslen Proliferation of Immature Tumor Vessels Is a Novel Marker of Clinical Progression in Prostate Cancer Cancer Res., June 1, 2009; 69(11): 4708 - 4715. [Abstract] [Full Text] [PDF]

				V. Venkateswaran, L. H. Klotz, M. Ramani, L. M. Sugar, L. E. Jacob, R. K. Nam, and N. E. Fleshner A Combination of Micronutrients Is Beneficial in Reducing the Incidence of Prostate Cancer and Increasing Survival in the Lady Transgenic Model Cancer Prevention Research, May 1, 2009; 2(5): 473 - 483. [Abstract] [Full Text] [PDF]

				A. M. Norris, M. Gentry, D. M. Peehl, R. D'Agostino Jr., and K. D. Scarpinato The Elevated Expression of a Mismatch Repair Protein Is a Predictor for Biochemical Recurrence After Radical Prostatectomy Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 57 - 64. [Abstract] [Full Text] [PDF]

				K. Gravdal, O. J. Halvorsen, S. A. Haukaas, and L. A. Akslen A Switch from E-Cadherin to N-Cadherin Expression Indicates Epithelial to Mesenchymal Transition and Is of Strong and Independent Importance for the Progress of Prostate Cancer Clin. Cancer Res., December 1, 2007; 13(23): 7003 - 7011. [Abstract] [Full Text] [PDF]

				R. Bedolla, T. J. Prihoda, J. I. Kreisberg, S. N. Malik, N. K. Krishnegowda, D. A. Troyer, and P. M. Ghosh Determining Risk of Biochemical Recurrence in Prostate Cancer by Immunohistochemical Detection of PTEN Expression and Akt Activation Clin. Cancer Res., July 1, 2007; 13(13): 3860 - 3867. [Abstract] [Full Text] [PDF]

				O. J. Halvorsen, K. Rostad, A. M. Oyan, H. Puntervoll, T. H. Bo, L. Stordrange, S. Olsen, S. A. Haukaas, L. Hood, I. Jonassen, et al. Increased Expression of SIM2-s Protein Is a Novel Marker of Aggressive Prostate Cancer Clin. Cancer Res., February 1, 2007; 13(3): 892 - 897. [Abstract] [Full Text] [PDF]

				C. J Burd, L. M Morey, and K. E Knudsen Androgen receptor corepressors and prostate cancer Endocr. Relat. Cancer, December 1, 2006; 13(4): 979 - 994. [Abstract] [Full Text] [PDF]

				Z. Dong, Y. Liu, S. Lu, A. Wang, K. Lee, L.-H. Wang, M. Revelo, and S. Lu Vav3 Oncogene Is Overexpressed and Regulates Cell Growth and Androgen Receptor Activity in Human Prostate Cancer Mol. Endocrinol., October 1, 2006; 20(10): 2315 - 2325. [Abstract] [Full Text] [PDF]

				I. M. Stefansson, H. B. Salvesen, and L. A. Akslen Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res., March 15, 2006; 66(6): 3303 - 3309. [Abstract] [Full Text] [PDF]

				I. M. Bachmann, O. J. Halvorsen, K. Collett, I. M. Stefansson, O. Straume, S. A. Haukaas, H. B. Salvesen, A. P. Otte, and L. A. Akslen EZH2 Expression Is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast J. Clin. Oncol., January 10, 2006; 24(2): 268 - 273. [Abstract] [Full Text] [PDF]

				A. J. Stephenson, P. T. Scardino, J. A. Eastham, F. J. Bianco Jr, Z. A. Dotan, C. J. DiBlasio, A. Reuther, E. A. Klein, and M. W. Kattan Postoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy J. Clin. Oncol., October 1, 2005; 23(28): 7005 - 7012. [Abstract] [Full Text] [PDF]

				A. Baldi, V. Ambrogi, D. Mineo, P. Mellone, M. Campioni, G. Citro, and T. C. Mineo Analysis of Cell Cycle Regulator Proteins in Encapsulated Thymomas Clin. Cancer Res., July 15, 2005; 11(14): 5078 - 5083. [Abstract] [Full Text] [PDF]

				R. Etzioni, S. Hawley, D. Billheimer, L. D. True, and B. Knudsen Analyzing Patterns of Staining in Immunohistochemical Studies: Application to a Study of Prostate Cancer Recurrence Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1040 - 1046. [Abstract] [Full Text] [PDF]

				L. Wu, D. C. Birle, and I. F. Tannock Effects of the Mammalian Target of Rapamycin Inhibitor CCI-779 Used Alone or with Chemotherapy on Human Prostate Cancer Cells and Xenografts Cancer Res., April 1, 2005; 65(7): 2825 - 2831. [Abstract] [Full Text] [PDF]

				G. V. Thomas, S. Horvath, B. L. Smith, K. Crosby, L. A. Lebel, M. Schrage, J. Said, J. De Kernion, R. E. Reiter, and C. L. Sawyers Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8351 - 8356. [Abstract] [Full Text] [PDF]

				V. Fradet, L. Lessard, L. R. Begin, P. Karakiewicz, A.-M. M. Masson, and F. Saad Nuclear Factor-{kappa}B Nuclear Localization Is Predictive of Biochemical Recurrence in Patients with Positive Margin Prostate Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8460 - 8464. [Abstract] [Full Text] [PDF]

				R. Foley, D. Hollywood, and M. Lawler Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease Endocr. Relat. Cancer, September 1, 2004; 11(3): 477 - 488. [Abstract] [Full Text] [PDF]

				V. Venkateswaran, N. E. Fleshner, L. M. Sugar, and L. H. Klotz Antioxidants Block Prostate Cancer in Lady Transgenic Mice Cancer Res., August 15, 2004; 64(16): 5891 - 5896. [Abstract] [Full Text] [PDF]

				G. Bepler, S. Sharma, A. Cantor, A. Gautam, E. Haura, G. Simon, A. Sharma, E. Sommers, and L. Robinson RRM1 and PTEN As Prognostic Parameters for Overall and Disease-Free Survival in Patients With Non-Small-Cell Lung Cancer J. Clin. Oncol., May 15, 2004; 22(10): 1878 - 1885. [Abstract] [Full Text] [PDF]

				I. M. Stefansson, H. B. Salvesen, and L. A. Akslen Prognostic Impact of Alterations in P-Cadherin Expression and Related Cell Adhesion Markers in Endometrial Cancer J. Clin. Oncol., April 1, 2004; 22(7): 1242 - 1252. [Abstract] [Full Text] [PDF]

				K. Struckmann, P. Schraml, R. Simon, K. Elmenhorst, M. Mirlacher, J. Kononen, and H. Moch Impaired Expression of the Cell Cycle Regulator BTG2 Is Common in Clear Cell Renal Cell Carcinoma Cancer Res., March 1, 2004; 64(5): 1632 - 1638. [Abstract] [Full Text] [PDF]

				E. S. Yang and K. L. Burnstein Vitamin D Inhibits G1 to S Progression in LNCaP Prostate Cancer Cells through p27Kip1 Stabilization and Cdk2 Mislocalization to the Cytoplasm J. Biol. Chem., November 21, 2003; 278(47): 46862 - 46868. [Abstract] [Full Text] [PDF]